BILLERICA, Mass.--(BUSINESS WIRE)--HydroCision Inc. (www.hydrocision.com) announced today the completion of a $12.7 million venture financing round, bringing total funding in HydroCision to approximately $28 million. Triathlon Medical Ventures (www.tmvp.com) was the lead investor in this ‘Series G’ round of financing. Additional investors included current HydroCision investors Oxford Bioscience Partners (www.oxbio.com), Newbury Ventures (www.newburyven.com) and Zero Stage Capital (www.zerostage.com), as well as other preferred shareholders and officers of HydroCision. The funding will be used to (a) complete a prospective controlled randomized trial for microdiscectomy to complement the initial clinical trial completed in microdiscectomy; (b) expand sales coverage and training in the U.S., Europe and Asia; (c) increase marketing communications support; and, (d) purchase capital equipment to increase speed to market and to reduce product cost. This is the first equity financing of the Company since March 2002.
